Table 1. Baseline characteristics of the included studies.
MHD, monthly headache days; MIDAS, migraine disability assessment; NCT, national clinical trial; NR, not reported; SD, standard deviation
| Study identifier | NCT identifier | Phase | Condition | Study group | n | Female (%) | Migraine attacks per month, mean (SD) | MHDs per month with acute medication use, mean (SD) | MIDAS baseline score, mean (SD) |
| Stauffer et al., 2018 [5] | NCT02614183 | 3 | Episodic migraine | Galcanezumab (120 mg) | 213 | 85 | 5.6 (1.7) | 7.4 (3.7) | 32.9 (28.2) |
| Galcanezumab (240 mg) | 212 | 82.6 | 5.7 (1.8) | 7.3 (3.3) | 36.1 (27.8) | ||||
| Placebo | 433 | 83.6 | 5.8 (1.7) | 7.4 (3.5) | 31.8 (27.3) | ||||
| Detke et al., 2018 [14] | NCT02614261 | 3 | Chronic migraine | Galcanezumab (120 mg) | 278 | 85 | NR | 15.1 (6.3) | 62.5 (49.5) |
| Galcanezumab (240 mg) | 277 | 82 | NR | 14.5 (6.3) | 69.2 (64.1) | ||||
| Placebo | 558 | 87 | NR | 15.5 (6.6) | 68.7 (57.4) | ||||
| Skljarevski et al., 2018 [10] | NCT02163993 | 2 | Episodic migraine | Galcanezumab (120 mg) | 70 | 84.6 | 4.6 (1.6) | NR | NR |
| Placebo | 137 | 79.6 | 4.7 (1.5) | NR | NR | ||||
| Skljarevski et al., 2018 [11] | NCT02614196 | 3 | Episodic migraine | Galcanezumab (120 mg) | 231 | 85.3 | 5.54 (1.8) | 7.47 (3.3) | 30.9 (27.9) |
| Galcanezumab (240 mg) | 231 | 85.7 | 5.66 (1.8) | 7.47 (3.3) | 32.8 (28.8) | ||||
| Placebo | 461 | 85.3 | 5. 7 (1.8) | 7.6 (3.4) | 34.3 (31.0) | ||||
| Sakai et al., 2020 [12] | NCT02959177 | 2 | Episodic migraine | Galcanezumab (120 mg) | 115 | 82.6 | 5.6 (1.7) | 7.3 (2.9) | 14.8 (18.1) |
| Galcanezumab (240 mg) | 114 | 84.2 | 5.5 (1.8) | 7.8 (3.0) | 13.7 (13.9) | ||||
| Placebo | 230 | 85.2 | 5.5 (1.7) | 7.4 (3.0) | 15.8 (19.3) | ||||
| Mulleners et al., 2020 [13] | NCT03559257 | 3 | Episodic migraine and chronic migraine | Galcanezumab (120 mg) | 232 | 84 | NR | 12.3 (6) | 50.9 (46) |
| Placebo | 230 | 88 | NR | 12.4 (6) | 51 (45.5) |